| Acute lymphocytic leukemia
Oncaspar vs Rylaze
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Oncaspar vs Rylaze with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRylaze has a higher rate of injection site reactions vs Oncaspar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rylaze but not Oncaspar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Oncaspar
Rylaze
At A Glance
IM injection or IV infusion
Every 14 days
PEGylated L-asparaginase
IM injection
Every 48 hours
Recombinant L-asparaginase
Indications
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia
- Precursor cell lymphoblastic lymphoma
Dosing
Acute lymphocytic leukemia 2,500 IU/m2 (age <=21 years) or 2,000 IU/m2 (age >21 years) IM or IV, no more frequently than every 14 days.
Acute lymphocytic leukemia, Precursor cell lymphoblastic lymphoma 25 mg/m2 IM every 48 hours, or 25 mg/m2 IM on Monday and Wednesday mornings and 50 mg/m2 IM on Friday afternoon, as replacement for a long-acting asparaginase product; premedicate with acetaminophen, H-1 blocker, and H-2 blocker 30-60 minutes prior to administration.
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR or any excipient
- History of serious thrombosis with prior L-asparaginase therapy
- History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy
- History of serious hemorrhagic events with prior L-asparaginase therapy
- Severe hepatic impairment
- History of serious hypersensitivity reactions to Erwinia asparaginase, including anaphylaxis
- History of serious pancreatitis during previous asparaginase therapy
- History of serious thrombosis during previous asparaginase therapy
- History of serious hemorrhagic events during previous asparaginase therapy
- Severe hepatic impairment
Adverse Reactions
Most common (>5%) Elevated transaminase, febrile neutropenia, hypertriglyceridemia, hypoalbuminemia, bilirubin increased, hyperglycemia, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, infections
Serious Anaphylaxis and serious hypersensitivity reactions, thrombosis, pancreatitis, glucose intolerance, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Coagulopathy, hepatic impairment, pancreatic cyst, veno-occlusive disease, anaphylactic shock, blood cholesterol increased, hyperglycemia, hyperammonemia, osteonecrosis, hemorrhage including CNS hemorrhage, thrombosis including superior sagittal sinus thrombosis
Most common (>20%) Abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, hypokalemia
Serious Febrile neutropenia, infection, drug hypersensitivity, pyrexia, nausea, dehydration, stomatitis, acute kidney injury, pancreatitis, diarrhea, viral infection
Postmarketing Veno-occlusive disease (VOD)
Pharmacology
ONCASPAR is a PEGylated L-asparaginase that catalyzes the conversion of L-asparagine to aspartic acid and ammonia, depleting plasma asparagine and killing leukemic cells that have low asparagine synthetase expression and depend on an exogenous asparagine source for survival.
Asparaginase erwinia chrysanthemi (recombinant)-rywn is a recombinant bacterial enzyme that catalyzes the conversion of L-asparagine to aspartic acid and ammonia, depleting plasma asparagine and killing leukemic cells that depend on exogenous asparagine for survival due to low asparagine synthetase expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Oncaspar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Rylaze
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Oncaspar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rylaze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Oncaspar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Rylaze
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$10/fillfill
JazzCares Copay Program: RylazeCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OncasparView full Oncaspar profile
RylazeView full Rylaze profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.